Samsung Bioepis To Present Follow-Up Trastuzumab Data
Partner Merck Launched Ontruzant In The US In April
Four years after initiating its comparative trastuzumab study, Samsung Bioepis has presented positive data that the firm hopes will help build confidence in the use of biosimilars for prescribers and patients. Meanwhile, the company also has good news for its SB11 ranibizumab biosimilar.
You may also be interested in...
Merck & Co has launched Ontruzant, the trastuzumab biosimilar developed and manufactured by Samsung Bioepis, in the US following a staggered approval process and earlier intellectual-property hurdles. The list price discount offered by the firm puts it in the middle of the pack among the four other biosimilar players currently on the market.
Samsung Bioepis and Biogen have agreed a marketing deal for ‘next generation’ biosimilars aflibercept and ranibizumab in the US, Canada, Europe, Japan and Australia, as well as providing an option for Biogen to extend its existing deal to market anti-TNF biosimilars adalimumab, etanercept and infliximab in Europe and adding a further option for rights to sell these three biosimilars in China.
Korean firm Celltrion is aiming to move production of insulin pens inside Korea “for the first time” and break the stranglehold of Big Pharma insulin players in the market by launching a biosimilar product in 2025.